AMG 133, AMG 133, AMG 133, AMG 133, Placebo for Maridebart cafraglutide
20220196
Phase 3 small_molecule active
Quick answer
AMG 133, AMG 133, AMG 133, AMG 133, Placebo for Maridebart cafraglutide for Atherosclerotic cardiovascular disease (ASCVD) and obesity or overweight is a Phase 3 program (small_molecule) at Amgen Technology (Ireland) UC with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Amgen Technology (Ireland) UC
- Indication
- Atherosclerotic cardiovascular disease (ASCVD) and obesity or overweight
- Phase
- Phase 3
- Modality
- small_molecule
- Status
- active